Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles.

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Adoptive T cell therapy (ATCT) shows promise for hematological malignancies and is being explored for solid tumors.
• Current ATCT methods often require known targets, limiting their application in solid tumors with diverse antigens.
• A novel approach is needed to target a broad repertoire of antigens in solid tumors.

Purpose of the Study:

• To investigate the use of immunostimulatory photothermal nanoparticles to generate tumor-specific T cells.
• To evaluate the efficacy of Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) in enhancing T cell responses against solid tumors.

Main Methods:

• Whole tumor cells were treated with PBNP-PTT to induce immunogenic cell death and enhance antigen presentation.
• Dendritic cells (DCs) were cultured with PBNP-PTT-treated tumor cells to stimulate T cells ex vivo.
• Expansion and functional activity of generated T cells were assessed against glioblastoma (GBM) cell lines.

Main Results:

• PBNP-PTT treatment effectively expanded tumor-specific CD4+ and CD8+ T cells (9- to 30-fold increase).
• These T cells exhibited significant tumor-specific interferon-ɣ secretion (up to 647-fold) and cytolytic activity (32-93% killing).
• The PBNP-PTT approach demonstrated superior T cell expansion and killing compared to traditional tumor cell lysate methods.

Conclusions:

• PBNP-PTT is a viable strategy for stimulating and expanding tumor-specific T cells ex vivo.
• This approach holds potential for adoptive T cell therapy in treating solid tumors.
• Further research is warranted to translate these findings into clinical applications.